Valuation: Eiger BioPharmaceuticals

Market Cap 12.59M 11.05M 10.17M 9.48M 17.88M 1.2B 18.24M 122M 47.4M 587M 47.26M 46.24M 2.04B P/E 2022
-0.51x
P/E 2023 -0.13x
Enterprise Value 27.95M 24.54M 22.58M 21.05M 39.69M 2.66B 40.5M 272M 105M 1.3B 105M 103M 4.54B EV / Sales 2022
-836,796x
EV / Sales 2023 1,605,487x
Free-Float
86.47%
Yield 2022 *
-
Yield 2023 -
3 years 1.1
Extreme 1.1
28.5
5 years 1.1
Extreme 1.1
300.64
10 years 1.1
Extreme 1.1
618.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 18/04/2022
Corporate Officer/Principal - 19/04/2024
Date Insider Type Main position Quantity % Market Cap.
31/10/23
Propel Bio Management LLC
BuyCompany 278,239 0.6281%
31/10/23
Propel Bio Management LLC
BuyCompany 24,332 0.0549%
18/10/23
Propel Bio Management LLC
OtherCompany 4,367,100 9.8588%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-59.75% 12.59M
+3.08%+9.20%-0.42%+5.47% 47.18B
+1.79%+9.69%+404.80%+594.07% 39.82B
-0.08%+9.36%+24.84%-8.17% 32.25B
+1.52%+5.07%+18.77%+61.00% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
+20.19%+12.07% - - 16.57B
-2.11%+6.40%+69.94%+128.25% 15.12B
-0.15%+4.94%+13.27%+17.71% 13.69B
+3.56%+3.26%+97.83%+92.34% 13.1B
Average +1.27%+6.63%+71.54%+95.75% 23.4B
Weighted average by Cap. +1.69%+7.41%+93.72%+136.73%

Financials

2022 2023
Net sales 13.48 11.84 10.9 10.15 19.15 1.28K 19.54 131.07 50.78 629.26 50.63 49.53 2.19K 15.77 13.85 12.75 11.88 22.4 1.5K 22.86 153.32 59.4 736.08 59.22 57.94 2.56K
Net income -96.78M -84.97M -78.21M -72.88M -137M -9.2B -140M -941M -364M -4.52B -363M -356M -15.72B -74.96M -65.82M -60.58M -56.45M -106M -7.13B -109M -729M -282M -3.5B -281M -275M -12.18B
Net Debt -63.29M -55.57M -51.15M -47.66M -89.89M -6.02B -91.71M -615M -238M -2.95B -238M -232M -10.28B 15.36M 13.49M 12.41M 11.57M 21.81M 1.46B 22.26M 149M 57.84M 717M 57.67M 56.42M 2.49B
Logo Eiger BioPharmaceuticals
Eiger Biopharmaceuticals LLC is a United States-based commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.
Employees
25
  1. Stock Market
  2. Stocks
  3. EIGR Stock